RNA aptamers selected to bind human immunodeficiency virus type 1 Rev in vitro are Rev responsive in vivo

Journal of Virology

Volumn 70, Issue 1, 1996, Pages 179-187

  Symensma, Tonia L ^a   Giver, Lori ^a   Zapp, Maria ^b   Takle, Garry B ^c   Ellington, Andrew D ^a  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Innovir Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; DNA FRAGMENT; DOUBLE STRANDED DNA; OLIGONUCLEOTIDE; REV PROTEIN; VIRUS MESSENGER RNA;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL LINE; CONTROLLED STUDY; GENE INSERTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HYBRID GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; REPORTER GENE; RNA SEQUENCE;

ANIMAL; BASE SEQUENCE; BINDING SITES; CELL LINE; CERCOPITHECUS AETHIOPS; DNA, VIRAL; GENE PRODUCTS, REV; GENES, REV; HIV-1; HUMAN; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; RNA, VIRAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029655644     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.1.179-187.1996     Document Type: Article

References (58)

1. Bahner, I., Z. Chen, X. J. Yu, Q. L. Hao, J. C. Guatelli, and D. B. Kohn. 1993. Comparison of trans-dominant inhibitory mutant human type 1 gene expression by retroviral vectors in human T lymphocytes. J. Virol. 67:3199-3207.
2. Bartel, D. P., M. L. Zapp, M. R. Green, and J. W. Szostak. 1991. HIV-1 Rev regulation involves recognition of non-Watson-Crick base-pairs in viral RNA. Cell 67:529-536.
3. Battiste, J. L., R. Tan, A. D. Frankel, and J. R. Williamson. 1994. Binding of an HIV Rev peptide to Rev-responsive element RNA induces formation of purine-purine base pairs. Biochemistry 33:2741-2747.
4. Calnan, B. J., S. Biancalana, D. Hudson, and A. D. Frankel. 1991. Analysis of arginine-rich peptides from the HIV Tat protein reveals unusual features of RNA-protein recognition. Genes Dev 5:201-210.
5. Cochrane, A. W., C.-H. Chen, and C. A. Rosen. 1990. Specific interaction of the human immunodeficiency virus Rev protein with a structured region in the env mRNA Proc Natl. Acad. Sci. USA 87:1198-1202.
6. Conrad, R., and A. D. Ellington. Biotech. Ann. Rev., in press.
7. Daly, T. J., K. S. Cook, G. S. Gray, T. E. Maione, and J. R. Rusche. 1989 Specific binding of HIV-1 recombinant Rev protein to the Rev-responsive element in vitro. Nature (London) 342:816-819.
8. Daly, T. J., P. Rennert, P. Lynch, J. K. Barry, M. Dundas, J. R. Rusche, R. C. Doten, M. Auer, and G. K. Farrington. 1993. Perturbation of the carboxy terminus of HIV-1 Rev affects multimerization on the Rev responsive element Biochemistry 32:8945-8954
9. Dayton, E. T., D. A. M. Konings, D. M. Powell, B. A. Shapiro, L. Butini, J. V. Maizel, and A. I. Dayton. 1992. Extensive sequence-specific information throughout the CAR/RRE, the target sequence of the human immunodeficiency virus type 1 Rev protein. J. Virol. 66:1139-1151.
10. Dayton, E. T., D. M. Powell, and A. I. Dayton. 1989. Functional analysis of CAR, the target sequence for the Rev protein of HIV-1. Science 246:1625-1629.
11. Emerman, M., R. Vazeux, and K. Peden. 1989. The rev gene product of the human immunodeficiency virus affects envelope-specific RNA localization. Cell 57:1155-1165.
12. Funkhauser, C., E. Izaurralde, Y. Adachi, P. Wingfield, and U. K. Laemmli. 1991. Specific complex of human immunodeficiency virus type 1 Rev and nucleolar B23 proteins' dissociation by the Rev response element. Mol. Cell. Biol. 11:2567-2575.
13. Felber, B. K., M. Hadzopoulou-Cladaras, C. Cladaras, T. Copeland, and G. N. Pavlakis. 1989. Rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc. Natl. Acad. Sci. USA 86:1495-1499.
14. Furuta, R. A., S. Kubota, M. Maki, Y. Miyazaki, T. Hattori, and M. Hatanaka. 1995. Use of a human immunodeficiency virus type 1 Rev mutant without nucleolar dysfunction as a candidate for potential AIDS therapy. J. Virol. 69:1591-1599.
15. Giver, L., D. Bartel, M. Zapp, A. Pawul, M. Green, and A. D. Ellington. 1993. Selective optimization of the Rev-binding element of HIV-1. Nucleic Acids Res. 23:5509-5516.
16. Hammarskjold, M.-L., J. Heimer, B. Hammarskjold, I. Swangwan, L. Albert, and D. Rekosh. 1989. Regulation of human immunodeficiency virus env expression by the rev gene product J. Virol. 63:1959-1966.
17. Hawley-Nelson, P., V. Ciccarone, G. Gebeyehu, J. Jessee, and P. L. Felgner. 1993. LipofectAMINE™ reagent: a new, higher efficiency polycationic liposome transfection reagent. FOCUS 15(3):73-79.
18. Heaphy, S., J. T. Finch, M. J. Gait, J. Karn, and M. Singh. 1991. Human immunodeficiency virus type 1 regulator of virion expression, rev. forms nucleoprotein filaments after binding to a purine-rich "bubble" located within the rev-responsive region of viral mRNAs. Proc. Natl. Acad. Sci. USA 88:7366-7370.
19. Holland, S. M., J. Ahmad, R. K. Maitra, P. Wingfield, and S. Venkatesan. 1990. Human immunodeficiency virus Rev protein recognizes a target sequence in Rev-responsive element RNA within the context of RNA secondary structure. J. Virol. 64:5966-5975.
20. Hope, T. J., X. Huang, D. McDonald, and T. G. Parslow. 1990. Steroid-receptor fusion of the human immunodeficiency virus type 1 Rev transactivator. mapping cryptic functions of the arginine-rich motif Proc. Natl. Acad. Sci USA 87:7787-7791.
21. Hope, T. J., N. P. Klein, M. E. Elder, and T. G. Parslow. 1992. Transdominant inhibition of human immunodeficiency virus type 1 Rev occurs through formation of inactive protein complexes. J. Virol. 66:1849-1855.
22. Hope, T. J., D. McDonald, X. Huang, J. Low, and T. G. Parslow. 1990. Mutational analysis of the human immunodeficiency virus type 1 Rev trans-activator essential residues near the amino terminus. J. Virol. 64:5360-5366.
23. Huang, X., T. J. Hope, B. L. Bond, D. McDonald, K. Grahl, and T. G. Parslow. 1991. Minimal Rev-response element for type 1 human immunodeficiency virus. J Virol 65:2131-2134.
24. Iwai, S., C. Pritchard, D. A. Mann, J. Karn, and M. J. Gait. 1992 Recognition of the high affinity binding site in rev-response element RNA by the human immunodeficiency virus type-1 rev protein Nucleic Acids Res. 20:6465-6472.
25. Kingston, R. E., C. Chen, and H. Okayama. 1990. Transfection of DNA into eukaryotic cells, p 9.1.1-9.1.9 (suppl. 14). In F. M Ausubel, R. Brent, R E. Kingston, D. D Moore, J G. Seidman, J. A. Smith, and K. Struhl (ed ), Current protocols in molecular biology. Greene Publishing Associates, New York.
26. Kjems, J., M. Brown, D. D. Chang, and P. A. Sharp. 1991 Structural analysis of the interaction between the human immunodeficiency virus Rev protein and the Rev response element. Proc. Natl. Acad. Sci. USA 88:683-687.
27. Kjems, J., B. J. Calnan, A. D. Frankel, and P. A. Sharp. 1992. Specific binding of a basic peptide from HIV-1 Rev. EMBO J. 11:1119-1129.
28. Leclerc, F., R. Cedergren, and A. D. Ellington. 1994. A three-dimensional model of the Rev-binding element of HIV-1 derived from analysis of aptamers Nature Struct. Biol. 1:293-300.
29. Lee, S.-W., H. F. Gallardo, E. Gilboa, and C. Smith. 1994. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. J. Virol 68:8254-8264
30. Lee, T. C., B. A. Sullenger, H. F. Gallardo, G. E. Ungers, and E. Gilboa. 1992. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells New Biol 4:66-74.
31. Leventis, R., and J. R. Silvius. 1990. Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic amphiphiles. Biochim Biophys. Acta 1023:124-132.
32. Lin, Y. S., and M. R. Green. 1989. Similarities between prokaryotic and eukaryotic cyclic AMP-responsive promoter elements Nature (London) 340:656-659
33. Lisziewicz, J., D. Sun, M. Klotman, S. Agrawal, P. Zamecnik, and R. Gallo. 1992. Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. Proc. Natl. Acad. Sci. USA 89:11209-11213.
34. Malim, M. H., S. Bohnlein, J. Hauber, and B. R. Cullen. 1989. Functional dissection of the HIV-1 Rev trans-activator - derivation of a trans-dominant repressor of Rev function Cell 58:205-214.
35. Malim, M. H., and B. R. Cullen. 1991. HIV-1 structural gene expression requires binding of multiple monomers to the RRE: implications for latency. Cell 65:241-248.
36. Malim, M. H., W. W. Freimuth, J. Liu, T. J. Boyle, H. K. Lylerly, B. R. Cullen, and G. J. Nabel. 1992. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp. Med. 176:1197-1201
37. Malim, M. H., J. Hauber, S.-Y. Le, J. V. Maizel, and B. R. Cullen. 1989. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature (London) 338:254-257.
38. Malim, M. H., L. S. Tiley, D. F. McCarn, J. R. Rusche, J. Hauber, and B. R. Cullen. 1990 HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. Cell 60:675-683.
39. Oliphant, A. R., C. J. Brandl, and K. Struhl. 1989 Defining the sequence specificity of DNA-binding proteins by selecting binding sites from random-sequence oligonucleotides' analysis of GCN4 protein. Mol. Cell. Biol. 9:2944-2949.
40. Olsen, H. S., S. Beidas, P. Dillon, C. A. Rosen, and A. W. Cochrane. 1991. Mutational analysis of the HIV-1 Rev protein and its target sequence the Rev responsive element J. Acquired Immune Defic. Syndr. 4:558-567.
41. Olsen, H. S., P. Nelbock, A. W. Cochrane, and C. A. Rosen. 1990. Secondary structure is the major determinant of HIV rev protein with RNA. Science 247:845-848
42. Peterlin, B. M., P. A. Luciw, P. J. Barr, and M. D. Walker. 1986. Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus Proc Natl. Acad. Sci. USA 83:9734-9738.
43. phe variants from a randomized library using two proteins. EMBO J. 12:2959-2967
44. Peterson, E. T., T. Pan, J. Coleman, and O. C. Uhlenbeck. 1994. In vitro selection of small RNAs that bind to Escherichia coli phenylalanyl-tRNA synthetase. J. Mol Biol. 242:186-192.
45. Pomerantz, R. J., T. Seshamma, and D. Trono. 1992. Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev potential implications for latency. J Virol 66:1809-1813.
46. Rossi, J. J., D. Elkins, J. A. Zaia, and S. Sullivan. 1992. Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems. AIDS Res Hum. Retroviruses 8:183-187
47. Ruhl, M., M. Himmelspach, G. M. Bahr, F. Hammerschmid, H. Jaksche, B. Wolff, H. Aschauer, G. K. Farrington, H. Probst, D. Bevec, and J. Hauber. 1993 Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating trans-activation. J. Cell Biol 123:1309-1320.
48. Sanchez-Pescador, R., M. D. Power, P. J. Barr, K. S. Steimer, M. M. Stempien, L. L. Brown-Shimer, W. W. Gee, A. Renard, A. Randolph, J. A. Levy, D. Dina, and P. A. Luciw. 1985. Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science 227:484-492.
49. Schneider, D., C. Tuerk, and L. Gold. 1992. Selection of high affinity RNA ligands to the bacteriophage R17 coat protein. J. Mol. Biol. 228:862-869.
50. Tan, R., L. Chen, J. A. Buettner, D. Hudson, and A. D. Frankel. 1993. RNA recognition by an isolated a helix. Cell 73:1031-1040.
51. Tan, R., and A. D. Frankel. 1994. Costabilization of peptide and RNA structure in an HIV Rev peptide-RRE complex. Biochemistry 33:14579-14585.
52. Tao, J., and A. D. Frankel. 1993 Electrostatic interactions modulate the RNA-binding and transactivation specificities of the human immunodeficiency virus and simian immunodeficiency virus Tat proteins. Proc. Natl. Acad. Sci. USA 90:1571-1575.
53. Tuerk, C., and S. MacDougal-Waugh. 1993. In vitro evolution of functional nucleic acids: high-affinity RNA Uganda of HIV-1 proteins. Gene 137:33-39.
54. Williamson, J. R. 1994 RNA origami. Nature Struct Biol. 1:270-272
55. Yu, M., E. Poeschla, and F. Wong-Staal. 1994. Progress towards gene therapy for HIV infection Gene Ther. 1:13-26.
56. Yuyama, N., J. Ohkawa, T. Koguma, M. Shirai, and K. Taira. 1994. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5′- and 3′-trimmed trans-acting ribozyme. targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev Nucleic Acids Res. 22:5060-5067.
57. Zapp, M. L., and M. R. Green. 1989. Sequence-specific RNA binding by the HIV-1 Rev protein. Nature (London) 342:714-716.
58. Zapp, M. L., T. J. Hope, T. G. Parslow, and M. R. Green. 1991. Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motil. Proc. Natl. Acad Sci. USA 88:7734-7738.